Financial Times FT.com

Amylin's Byetta: physicians remain skeptical of drug's real-world benefit

By Kimberly Ha and Sasha Damouni in New York

Published: August 21 2008 13:30 | Last updated: August 21 2008 13:30

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)